BackArriVent BioPharma Overview

ArriVent BioPharma Long Term Debt

Latest long-term debt for AVBP: $320K.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$320000.00

Peer average / median

Loading

ArriVent BioPharma Long Term Debt History

Loading

ArriVent BioPharma vs. peers: Long Term Debt Comparison

Loading

ArriVent BioPharma Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

ArriVent BioPharma (AVBP) FAQ

The latest long-term debt for AVBP is $320K as of March 2026. In the prior-year period, the figure was $0. Investors often review this figure alongside ArriVent BioPharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, AVBP's long-term debt moved from $0 to $320K. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in ArriVent BioPharma's operating scale or balance-sheet position.

A long-term debt figure of $320K for AVBP is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting AVBP's long-term debt ($320K), review year-over-year change from $0, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.